Yes. A separate Nao psychiatric visit is not automatically required when an outside psychiatrist actively prescribes and manages the treatment. Nao must accept the order and records, coordinate patient-specific medication delivery, confirm an eligible clinic and trained staff, and schedule the administration visit. Patients who need prescribing or ongoing psychiatric management can start with Nao psychiatry instead.
Same-day administration is not promised. An outside-order pathway starts with order and record review; a Nao-managed pathway starts with a psychiatric evaluation. In either path, dose timing, tolerability history, medication access, trained staff, and site capability must be confirmed first.
Nao evaluates product-specific pathways for aripiprazole, risperidone, paliperidone, and selected older depot antipsychotics. Perseris U.S. availability ended May 31, 2026, so it is covered only as treatment-continuity information. The team confirms eligibility and site capability for each currently available medicine.
The evaluation may be virtual. The care team confirms the administration clinic separately after reviewing the product, delivery path, storage, staff, monitoring, and appointment timing.
Contact the responsible prescriber before another dose. Missed-dose instructions differ by product and by the time since the last injection; some medicines require oral coverage or re-initiation.
A switch is not automatic. A psychiatric prescriber must confirm the diagnosis, prior response, oral tolerability, interactions, initiation regimen, and whether the expected benefits outweigh the risks.
Coverage varies by diagnosis, plan, benefit channel, prior authorization, specialty pharmacy, and administration site. The evaluation, medicine, and administration may process separately.
Send the current medication list, diagnosis and treatment history, last injection or oral dose, due date, prior side effects, relevant monitoring, pharmacy information, and the outside prescriber's contact details.